103808-71-5

Upstream product

• 622-40-2 2-(morpholin-4-yl)ethanol 
• 540-38-5 p-Iodophenol 
• 3647-69-6 4-(2-chloroethyl)morpholine hydrochride 

Downstream Products

• 1344700-80-6 (2S)-N-(benzyloxy)-N',2-dimethyl-2-[methyl({4'-[2-(morpholin-4-yl)ethoxy]biphenyl-4-yl}carbonyl)amino]propanediamide 
• 690636-28-3 4-(2-( 4-( 4, 4, 5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethyl)morpholine 
• 339058-36-5 (Z)-4-(2'-(4''-(1''',3'''-diphenylpent-2'''-en-2'''-yl)phenoxy)ethyl)morpholine 
• 554430-14-7 5-(tert-butyl-dimethyl-silyloxy)-2-(7-(tert-butyl-dimethyl-silyloxy)-4-{hydroxy-[4-(2-morpholin-4-yl-ethoxy)-phenyl]-methyl}-2H-chromen-3-yl)-phenol 

Relevant academic research and scientific papers

COMPOUNDS FOR MODULATING DDAH AND ADMA LEVELS, AS WELL AS METHODS OF USING THEREOF TO TREAT DISEASE

Disclosed are compounds that can modulate DDAH and the amount of asymmetric dimethylarginine (ADMA) in a subject. Also provided are pharmaceutical compositions comprising these compounds, as well as methods of using these compositions to treat and/or prevent diseases associated with elevated or low levels of DDAH and ADMA.

NOVEL HYDROXAMIC ACID DERIVATIVE

Provided is a novel compound which is useful as a pharmaceutical composition by inhibiting an LpxC activity, thereby exhibiting potent antimicrobial activity against gram-negative bacteria including Pseudomonas aeruginosa and its drug resistant bacteria. Provided is a hydroxamic acid derivative represented by the following general formula [1] or a pharmaceutically acceptable salt thereof:

Furanopyridine derivatives and methods of use

The present invention relates to furanopyridine compounds having the general Formula I: and stereoisomers, tautomers, solvates, pharmaceutically acceptable salts and derivatives, and prodrugs thereof. The invention also includes pharmaceutical composition